Sichuan Province Shuzhong Pharmacy Co., Ltd.

The main purpose of the study is to investigate the pharmacokinetic characteristics of a single oral dose (fasting/after meals) of 15 mg of the test preparation rivaroxaban tablets and the reference preparation rivaroxaban tablets in healthy adult Chinese participants, and to evaluate the bioequivalence of the two preparations under fasting and after meals conditions. The secondary purpose of the study is to evaluate the safety of a single oral dose of 15 mg (fasting/after meals) of the test preparation and the reference preparation in healthy adult Chinese participants.

Celecoxib capsules (specification: 0.2g) produced by Sichuan Yike Pharmaceutical Co., Ltd. were used as the test preparation, and celecoxib capsules (trade name: Celebrex®, specification: 0.2g) produced by Pfizer Pharmaceuticals LLC were used as the reference preparation. According to the relevant regulations of bioequivalence test, the bioequivalence of the two preparations in healthy humans was investigated.

Main purpose: Diclofenac sodium sustained-release tablets (specification: 0.1g) of Sichuan Yike Pharmaceutical Co., Ltd. were used as the test preparation, and diclofenac sodium sustained-release tablets (trade name: VOLTAREN®, specification: 100mg) certified by Novartis Pharma GmbH were used as the reference preparation. According to the relevant provisions of the bioequivalence test, the bioequivalence of the two preparations in healthy humans was investigated. Secondary purpose: To observe the safety of the test preparation and the reference preparation in healthy subjects.